Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study)Joint Development Agreement • November 17th, 2022
November 18, 2021, Osaka, Japan- Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and ActualEyes Inc. (Kyotanabe, Kyoto, hereinafter “ActualEyes”) have signed a joint development agreement on Phase II clinical trial (Phase II a / Proof of Concept study) toward global development for sirolimus eye drops (Santen development code “STN1010904*” and ActualEyes development code “AE- 001”) for treating Fuchs endothelial corneal dystrophy (FECD).
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study)Joint Development Agreement • November 18th, 2021
November 18, 2021, Osaka, Japan- Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and ActualEyes Inc. (Kyotanabe, Kyoto, hereinafter “ActualEyes”) have signed a joint development agreement on Phase II clinical trial (Phase II a / Proof of Concept study) toward global development for sirolimus eye drops (Santen development code “STN1010904*” and ActualEyes development code “AE- 001”) for treating Fuchs endothelial corneal dystrophy (FECD).
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study)Joint Development Agreement • November 17th, 2021
November 18, 2021, Osaka, Japan- Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and ActualEyes Inc. (Kyotanabe, Kyoto, hereinafter “ActualEyes”) have signed a joint development agreement on Phase II clinical trial (Phase II a / Proof of Concept study) toward global development for sirolimus eye drops (Santen development code “STN1010904*” and ActualEyes development code “AE- 001”) for treating Fuchs endothelial corneal dystrophy (FECD).